These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24231843)

  • 41. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
    Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN
    J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
    Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
    J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer.
    Hinotsu S; Akaza H; Naito S; Ozono S; Sumiyoshi Y; Noguchi S; Yamaguchi A; Nagamori S; Terai A; Nasu Y; Kume H; Tomita Y; Tanaka Y; Samma S; Uemura H; Koga H; Tsushima T
    BJU Int; 2011 Jul; 108(2):187-95. PubMed ID: 21176079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial.
    Kamat AM; Dickstein RJ; Messetti F; Anderson R; Pretzsch SM; Gonzalez GN; Katz RL; Khanna A; Zaidi T; Wu X; Grossman HB; Dinney CP
    J Urol; 2012 Mar; 187(3):862-7. PubMed ID: 22245325
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A 2-week maintenance regimen of intravesical instillation of bacillus Calmette-Guerin is safe, adherent and effective in patients with non-muscle-invasive bladder cancer: a prospective, multicenter phase II clinical trial.
    Kanagawa Urological Research Group (KURG)
    Jpn J Clin Oncol; 2012 Sep; 42(9):813-9. PubMed ID: 22761255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer.
    Alvarez-Múgica M; Cebrian V; Fernández-Gómez JM; Fresno F; Escaf S; Sánchez-Carbayo M
    J Urol; 2010 Oct; 184(4):1507-13. PubMed ID: 20723929
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
    Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
    J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data.
    Liem EIML; Oddens JR; Vernooij RWM; Li R; Kamat A; Dinney CP; Mengual L; Alcaraz A; Izquierdo L; Savic S; Thalmann GN; Bubendorf L; Sylvester RJ; de Reijke TM
    J Urol; 2020 Feb; 203(2):283-291. PubMed ID: 31549936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
    Gontero P; Sylvester R; Pisano F; Joniau S; Vander Eeckt K; Serretta V; Larré S; Di Stasi S; Van Rhijn B; Witjes AJ; Grotenhuis AJ; Kiemeney LA; Colombo R; Briganti A; Babjuk M; Malmström PU; Oderda M; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha EK; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Johansson R; Frea B; Soukup V; Xylinas E; Dalbagni G; Karnes RJ; Shariat SF; Palou J
    Eur Urol; 2015 Jan; 67(1):74-82. PubMed ID: 25043942
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial.
    van der Meijden AP; Brausi M; Zambon V; Kirkels W; de Balincourt C; Sylvester R;
    J Urol; 2001 Aug; 166(2):476-81. PubMed ID: 11458050
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma.
    Kondylis FI; Demirci S; Ladaga L; Kolm P; Schellhammer PF
    J Urol; 2000 Apr; 163(4):1120-3. PubMed ID: 10737479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
    Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
    Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
    Herr HW; Badalament RA; Amato DA; Laudone VP; Fair WR; Whitmore WF
    J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
    Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
    J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased risk of bladder cancer recurrence due to bacillus Calmette-Guérin shortage in Brazil.
    Murta CB; Hayek KKRE; Dias BC; Yorioka MAW; Cassao VD; Claro JFA
    Rev Assoc Med Bras (1992); 2024; 70(5):e20231116. PubMed ID: 38775530
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P; Holmäng S
    BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
    Prasad SM; Eyre S; Loughlin KR
    Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.